Status:
COMPLETED
RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR
Lead Sponsor:
Biogen
Collaborating Sponsors:
AbbVie
Conditions:
MItochondrial Myopathies
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Mitochondrial myopathies are a multisystemic group of disorders that are characterized by a wide range of biochemical and genetic mitochondrial defects and variable modes of inheritance. Currently the...
Eligibility Criteria
Inclusion
- Have mitochondrial myopathy as evidenced by the following 2 criteria (must meet both):
- Have a history of exercise intolerance with or without weakness and/or progressive exercise intolerance (in which modest exercise typically provokes heaviness, weakness, aching of active muscles, or tachycardia)
- Have a known primary mitochondrial DNA mutation or a nuclear DNA defect that is associated with reduced activity of at least 1 mitochondrially encoded respiratory chain complex
- Be male or female and ≥18 years of age and ≤75 years of age
- Have no changes to exercise regimen within 30 days prior to Study Day 1 and be willing to remain on the same exercise regimen during the 16-week study period
- Have the ability to complete maximal exercise testing
- Have a peak workload during maximal exercise testing of ≤ 1.5 W/kg
- Be able to swallow capsules
Exclusion
- Have uncontrolled diabetes (HbA1c \>11.0%)
- Have B-type natriuretic peptide level \>200 pg/mL
- Have a history of clinically significant left-sided heart disease and/or clinically significant cardiac disease
- Have known active fungal, bacterial, and/or viral infection, including human immunodeficiency virus or hepatitis virus (B or C)
- Have known or suspected active drug or alcohol abuse
- Have clinically significant abnormalities of clinical hematology or biochemistry, including but not limited to elevations greater than 1.5 times the upper limit of normal of aspartate aminotransferase, alanine aminotransferase, or creatinine
- Have any abnormal laboratory test value or serious pre-existing medical condition that, in the opinion of the investigator, would put the patient at risk by study enrollment
- Have taken any of the following drugs within 7 days prior to Study Day 1 or plan to take any of these drugs during the time of study participation:
- Sensitive substrates for cytochrome P450 2C8 or 3A4 (e.g., repaglinide, midazolam, sildenafil)
- Substrates for p-glycoprotein transporter (e.g., ambrisentan, digoxin)
- Have participated in any other interventional clinical study within 30 days prior to Study Day 1
- Have a cognitive impairment that may preclude ability to comply with study procedures
Key Trial Info
Start Date :
May 5 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2017
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT02255422
Start Date
May 5 2015
End Date
November 30 2017
Last Update
June 5 2025
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA
Los Angeles, California, United States, 90095
2
Mass General Hospital
Boston, Massachusetts, United States, 02114
3
Akron Children's Hospital
Akron, Ohio, United States, 44308
4
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104